Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1997-06-20
2001-08-14
Elliott, George C. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S573000, C424S572000, C424S422000, C424S423000, C424S424000, C424S425000, C424S093200, C424S093210, C435S006120, C435S455000, C435S375000, C435S377000, C536S023100, C536S024100, C536S024500
Reexamination Certificate
active
06274562
ABSTRACT:
BACKGROUND OF THE INVENTION
The IGF-1 receptor is expressed in many cell types including fibroblasts, epithelial cells, smooth muscle cells, chondrocytes, osteoblasts and several lineages of hemopoietic cells which have IGF-1 receptors and an absolute requirement for IGF-1 for growth in cultures. A review of human cells expressing the IGF-1 receptor and requiring IGF-1 for growth can be found in Baserga and Rubin,
Critical Reviews in Eukaryote Gene Expression,
1993, 3: 47-61; and Goldring and Goldring,
Eukaryote Gene Expression
1991, 1, 301-326. Macaulay,
Br. J. Cancer
1992, 65,311-320, has reviewed the expression of insulin-like growth factors (both IGF-1 and IGF-2) and their receptors in human cancer. Recently, it was shown that IGF-1 peptide analogs may be useful for inhibiting the growth of IGF-1 dependent cells (Pietrzkowski et al.,
Cancer Res.
1993, 53, 1102-1106). Antisense oligonucleotides to mRNA coding for IGF-1 was used to transform rat glioblastoma cells. The cells reversed the transformed phenotype, and acted immunogenic against the parent glioblastoma cell line, completely inhibiting its growth. Trojan et al.
Science,
1993, 259, 94-97 and Trojan et al.,
Proc. Natl. Acad. Sci. U.S.A.,
1992, 89, 4874-4878. However, effective methods of inhibiting growth and causing differentiation of cells are still greatly desired.
SUMMARY OF THE INVENTION
Methods of inhibiting the growth and causing differentiation of undifferentiated cells with antisense oligonucleotides complementary to a region of the IGF-1 receptor are provided. The antisense oligonucleotides of the present invention comprise sequences complementary to regions of IGF-1 receptor RNA. The oligonucleotides comprise a sequence complementary to a region selected from the sequence of IGF-1 receptor. The antisense oligonucleotides include DNA sequences; and antisense RNA oligonucleotides produced from an expression vector. Each of the antisense oligonucleotides of the present invention are complementary to regions of the IGF-1 receptor sequence. The antisense oligodeoxynucleotide of the present invention comprises a sequence complementary to codons −29 to −24 of the signal sequence, for example, SEQ ID NO: 4. The signal sequence of IGF-1 receptor is a 30 amino acid sequence. Contemplated by this definition are fragments of oligos within the 30 amino acid signal sequence. Alternatively, fragments of oligos within SEQ ID NO: 4 are also contemplated. The antisense oligoribodeoxyoligonucleotide produced from an expression vector comprises a sequence complementary to codons 1 to 309 of the IGF-1 receptor, SEQ ID NO: 7 and
FIGS. 7A-7G
. See Ullrich et al.,
EMBO J.,
1986, 5:2503. Contemplated by this definition are fragments of oligos within the coding sequence for the IGF-1 receptor.
REFERENCES:
patent: 5271941 (1993-12-01), Cho-Chung
patent: WO 93/20691 (1993-10-01), None
Holt et al.,Proc. Natl. Acad. Sci. USA83:4794-4798 (Jul. 1986).
Wickstrom et al., “Antisense DNA Methylphosphonate Inhibition Of c-myc Gene Expression In Transgenic Mice”,The FASEB Journal5(5):A1443 (Mar. 15, 1991).
Talavera et al.,Cancer Research50:3019-3024 (May 15, 1990).
Porcu et al.,Molecular and Cellular Biology12(11):5069-5077 (1992).
Pietrzkowski et al.,Cell Growth&Differentiation3:199-205 (Apr. 1992).
Pietrzkowski et al.,Molecular and Cellular Biology12(9):3883-3889 (Sep. 1992).
Pietrzkowski et al.,Cancer Research53:1102-1106 (Mar. 1, 1993).
Milligan et al.,Journal of Medicinal Chemistry36(14):1923-1937 (Jul. 9, 1993).
Culver et al.,TIG10(5):174-178 (May 1994).
Dzau et al.,TIBTECH11 (May 1993).
Hug et al.,Biochimica et Biophysica Acta1097:1-17 (1991).
Weiss,Science News139:108-109 (Feb. 16, 1991).
Westermann et al.,Biomed. Biochim. Acta48:85-93 (1989).
Tseng et al.,Cancer Gene Therapy1(1):65-71 (Mar. 1994).
Stein et al.,Science261:1004-1012 (Aug. 20, 1993).
Uhlmann et al.,Chemical Reviews90(4):543-584 (Jun. 1990).
Mercola et al.,Biochemical and Biophysical Research Communications147(1):288-294 (Aug. 1987).
Ullrich et al.,EMBO J.5:2503-12 (1986).
Trojan et al.,The Journal of Cell Biology115(3)Pt.2:263a (Nov. 1991).
Lahm et al.,The European Journal Of Cancer27(3):S79 (1991).
Stein,J. Cell. Physiol.99:43-54 (1979).
Agrawal, S., “Antisense Oligonucleotides: Towards Clinical Trials” TIBTECH vol. 14:376-387, Oct. 1996.*
Branch A., “A Good Antisense Molecule is Hard to Find” TIBS vol. 23:45-50, Feb. 1998.*
Pietrzkowski et al., 1991, FASEB Abstract 7268.
Rohlik et al., “An Antibody To The Receptor For Insulin-Like Growth Factor I Inhibits The Growth Of MCF-7 Cells In Tissue Culture,”Biochem. Biophys. Res. Comm., 1987, 149, 276-281.
Shapiro et al., “Antisense-mediated reduction in insulinlike growth factor-1 receptor expression suppresses the malignant phenotype of a human rhabdosarcoma,” Proceedings of the 83rdAnnual Meeting of the American Association for Cancer Research, vol. 33, p. 354, Mar. 1992.
Surmacz et al., “The role of IGF1 receptor in regulation of cdc2 mRNA levels in fibroblasts,”Experimental Cell Research, vol. 199, pp. 275-278, 1992.
Agrawal et al.,Antisense Oligonucleotide Based Therapeutic Approach: From Laboratory to Clinical Trials, Antisense Therapy: Efficacy and Delivery of Antisense&Ribozyme Oligonucleotides(Feb. 23-25, 1995 London).
Arad, et al.,Biochem. Biophy. Acta.859:88-94 (1986).
Baker et al.,Cell75:73-82 (1993).
Baron-Van Euvrooren et al.,J. Neurosci. Res.(2): 244-53 (1991) Abstract.
Baserga et al.,Critical Reviews in Eukaryote Gene Expression, 3:47-61 (1993).
Baserga,Cancer Research55:249-252 (1995).
Bayever et al.,Hematological Oncology12:9-14 (1994).
Brown,Washington PostA1 & A22 (Dec. 8, 1995).
Chomczynski et al.,Anal. Biochem.162:156-159 (1987).
Coghlan,New Scientist14-15 (Nov. 25, 1995).
Craig et al.,Cell16:575-588 (Mar. 1979).
de Fabritiis et al.,Leukemia9(4):662-664 (1995).
Feinberg et al.,Anal. Biochem.132:6-13 (1983).
Floros et al.,Exp. Cell Res.132:215-223 (1981).
Gennaro, Alfonso, ed., Remington's Pharmaceutical Sciences, 18th Edition, 1990, Chapter 74, by A.H. Der Marderosian, “Biotechnology & Drugs”, pp. 1416-1431.
Goldring et al.,Eukaryote Gene Expression1:301-326 (1991).
Gritz et al.,Gene25:179-188 (1983).
Gura,Science270:575-577 (Oct. 27, 1995).
Hijiya et al.,Proc. Natl. Acad. Sci. USA91:4499-4503 (1994).
Jat et al.,Mol. Cell. Biol.9(4):1672-1681 (1989).
Keleko et al.,Mol. Cell. Biol.10:464-473 (Feb. 1990).
Lammers et al.,EMBO J.8(5):1369-1375 (1989).
Lipson et al.,Proc. Natl. Acad. Sci. USA86:9774-9777 (Dec. 1989).
Liu et al.,Cell75:59-72 (Oct. 8, 1993).
Long et al.,Cancer Research55:1006-1009 (1995).
Mccaulay,Br. J. Cancer65:311-320 (1992).
Marks et al.,Mol. Endocrinol.5(8):1158-1168 (1991).
McCubrey et al.,Blood78:921-929 (Aug. 15, 1991).
Nabel et al.,Proc. Natl. Acad. Sci.90:11307-11311 (Dec. 1993).
Pietrzkowski et al.,Cancer Res.52:6447-6451 (Dec. 1, 1992).
Radna et al.,Mol. Cell. Biol.9:3093-3096 (Jul. 1989).
Rappolee et al.,J. Cell. Biochem.39:1-11 (1989).
Ratajczak et al., Oligonucleotide Therapeutics for Human Leukemia, Antisense Therapy: Efficacy and Delivery of Antisense & Ribozome Oligonucleotide (presented Feb. 23-24, 1995, London) pp. 1-11.
Reiss et al.,Oncogene7:2243-2248 (1992).
Resnick-Silverman et al.,J. Virol.65:2845-2852 (Jun. 1991).
Resnicoff et al.,Cancer Research54:4848-4850 (1994).
Resnicoff et al.,Cancer Research55:2463-2469 (1995).
Sell et al.,PNAS90:11217-11221 (Dec. 1993).
Shen et al.,Mol. Cell. Biol.2(9):1145-1154 (Sep. 1982).
Skorski et al.,Proc. Natl. Acad. Sci.vol. 91:4504-4508 (May 1994).
Tegtmeyer,J. Virol.15(3):613-618 (Mar. 1975).
Thomas,Methods Enzymol.100:255-266 (1983).
Thompson et al.,Virology178:15-34 (1990).
Todaro et al.,J. Cell Biol.17:299-313 (1963).
Trojan et al.,Proc. Natl. Acad. Sci. USA89:4874-4878 (1992).
Trojan et al.,Science259:94-97 (Jan. 1, 1993).
Wetmur,Critical Reviews in Biochemistry and Molecular Biology26(3/4):227-259 (1991).
Wharton et al.,Cell Growth and DivisionChapter 10, pp. 139-153 (1989).
Yamori et al.,Cancer Res.51:5859-5865 (Nov. 1, 1991).
Loke et al.,Current Topics in Microbiology and Immunology141:282-289
Baserga Renato
Rubin Raphael
Sell Christian
Elliott George C.
McGarry Sean
Thomas Jefferson University
Woodcock Washburn Kurtz Mackiewicz & Norris LLP
LandOfFree
Method of inhibiting the proliferation and causing the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting the proliferation and causing the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting the proliferation and causing the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2533307